CHI’s NK Cell-Based Cancer Immunotherapy Symposium, September 19 in Boston
Reporter: Aviva Lev-Ari, PhD, RN
Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 2016)
FEATURED SESSION: Natural killer (NK) cells have been known to have advantages over T cells, yet their therapeutic potential in the clinic has been largely unexplored. Cambridge Healthtech Institute’s NK Cell-Based Cancer Immunotherapy Symposium, September 19 in Boston, is dedicated to the exploration of utilizing NK cells for new adoptive cell therapies, including updates from ongoing clinical studies. NK CELL IMMUNO-ONCOLOGY AND CLINICAL STUDIES Harnessing Adaptive NK Cells in Cancer Therapy Karl-Johan Malmberg, M.D., Ph.D., Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
Update on Systemic and Locoregional Cancer Immunotherapy with IL-21-Expanded NK Cells Dean Anthony Lee, M.D., Ph.D., Professor, Pediatrics; Director, Cellular Therapy and Cancer Immunotherapy Program, Nationwide Childrens Hospital; James Comprehensive Cancer Center/Solove Research Institute, The Ohio State University
|
|
|||
|
||||
|
||||
DiscoveryOnTarget.com | Register by August 12 to SAVE up to $200 | Download PDF Agenda |
||||
Cambridge Healthtech Institute | 250 First Avenue, Suite 300, Needham, MA 02494 | www.healthtech.com | 781-972-5400 |
SOURCE
From: NK Cell Symposium <heidio@healthtech.com>
Date: Tuesday, August 9, 2016 at 1:40 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: NK Cells for Adoptive Therapies: The Future of Cancer Immunotherapy?
Leave a Reply